Literature DB >> 8329730

Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation.

M A Nauck1, M Büsing, C Orskov, E G Siegel, J Talartschik, A Baartz, T Baartz, U T Hopt, H D Becker, W Creutzfeldt.   

Abstract

Insulin secretion is stimulated better by oral than by intravenous glucose (incretin effect). The contribution of the autonomic nervous system to the incretin effect after oral glucose in humans is unclear. We therefore examined nine type 1 diabetic (insulin-dependent) patients with end-stage nephropathy, studied after combined heterotopic pancreas and kidney transplantation, and 7 non-diabetic kidney recipients (matched for creatinine clearance and immunosuppressive medication). The release of gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) immunoreactivity and B cell secretory responses (IR insulin and C-peptide) to oral (50 g) and "isoglycaemic" intravenous glucose (identical glycaemic profile) were measured by radioimmunoassay. The difference in B cell responses between the two tests represents the contribution of the enteroinsular axis to the response after oral glucose (incretin effect). Insulin responses after the oral glucose challenge were similar in the two patient groups despite systemic venous drainage of the pancreas graft in the pancreas-kidney-transplanted group. In both groups GIP and GLP-1 increased after oral but not after intravenous glucose, and B cell secretory responses were significantly smaller (by 55.2 +/- 7.7% and 46.5 +/- 12.5%, respectively) with "isoglycaemic" intravenous glucose infusions. The lack of reduction in the incretin effect in pancreas-kidney-transplanted patients, whose functioning pancreas is denervated, indicates a lesser role for the nervous system and a more important contribution of circulating incretin hormones in mediating the enteroinsular axis in man.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8329730     DOI: 10.1007/bf00572873

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  39 in total

Review 1.  The incretin concept today.

Authors:  W Creutzfeldt
Journal:  Diabetologia       Date:  1979-02       Impact factor: 10.122

2.  Incretin effect due to increased secretion and decreased clearance of insulin in normal humans.

Authors:  L T Shuster; V L Go; R A Rizza; P C O'Brien; F J Service
Journal:  Diabetes       Date:  1988-02       Impact factor: 9.461

3.  Glucose turnover and insulin secretion in dogs with pancreatic allografts.

Authors:  A Jakob; F Largiadèr; E R Froesch
Journal:  Diabetologia       Date:  1970-08       Impact factor: 10.122

4.  Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.

Authors:  S Mojsov; G C Weir; J F Habener
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

5.  Impairment of stimulated insulin release from the isolated perfused rat pancreas by cyclosporine pretreatment.

Authors:  F Stöckmann; H C Fehmann; B Göke; E G Siegel; W Creutzfeldt
Journal:  Transplantation       Date:  1989-09       Impact factor: 4.939

6.  Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels.

Authors:  D K Andersen; D Elahi; J C Brown; J D Tobin; R Andres
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

7.  Kinetics of circulating endogenous insulin, C-peptide, and proinsulin in fasting nondiabetic man.

Authors:  J H Henriksen; B Tronier; J B Bülow
Journal:  Metabolism       Date:  1987-05       Impact factor: 8.694

8.  Attempts at perfect normalization of glucose tolerance test of severe diabetics by artificial beta cell.

Authors:  W Kerner; C Thum; G Tamás; W Beischer; A H Clemens; E F Pfeiffer
Journal:  Horm Metab Res       Date:  1976-07       Impact factor: 2.936

9.  Influence of the oral cavity on insulin release in the rat.

Authors:  A B Steffens
Journal:  Am J Physiol       Date:  1976-05

10.  Intravenous glucose tolerance and pancreatic islet beta-cell function in patients with multiple sclerosis during 2-yr treatment with cyclosporin.

Authors:  R P Robertson; G Franklin; L Nelson
Journal:  Diabetes       Date:  1989-01       Impact factor: 9.461

View more
  7 in total

Review 1.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

2.  Determinants of a normal (versus impaired) oral glucose tolerance after combined pancreas-kidney transplantation in IDDM patients.

Authors:  F Pfeffer; M A Nauck; S Benz; A Gwodzinski; R Zink; M Büsing; H D Becker; U T Hopt
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

Review 3.  The effect of glucagon-like peptide 1 on cardiovascular risk.

Authors:  Jacob Sivertsen; Jaya Rosenmeier; Jens J Holst; Tina Vilsbøll
Journal:  Nat Rev Cardiol       Date:  2012-01-31       Impact factor: 32.419

Review 4.  Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?

Authors:  Juris J Meier; Michael A Nauck
Journal:  Diabetes       Date:  2010-05       Impact factor: 9.461

5.  Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications.

Authors:  Jeffrey R Unger; Christopher G Parkin
Journal:  Diabetes Ther       Date:  2011-01-18       Impact factor: 2.945

6.  Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty.

Authors:  Astrid Plamboeck; Simon Veedfald; Carolyn F Deacon; Bolette Hartmann; André Wettergren; Lars B Svendsen; Søren Meisner; Claus Hovendal; Filip K Knop; Tina Vilsbøll; Jens J Holst
Journal:  Eur J Endocrinol       Date:  2013-07-06       Impact factor: 6.664

Review 7.  In Vivo Models for Incretin Research: From the Intestine to the Whole Body.

Authors:  Tae Jung Oh
Journal:  Endocrinol Metab (Seoul)       Date:  2016-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.